• GPR35-KLF5 Circuitry Enables Epithelial Repair in DSS Coliti

  2026-07-14

  This study identifies a tryptophan metabolic gatekeeping mechanism wherein GPR35 senses damage signals via kynurenic acid, activating KLF5-driven repair in intestinal epithelial cells. The findings clarify how epithelial cells decode mucosal injury in ulcerative colitis, providing a mechanistic framework for optimizing DSS-induced colitis models and therapeutic targeting of epithelial regeneration.

• Molidustat (BAY85-3934): Advancing HIF Stabilization in Rena

  2026-07-14

  This article explores the mechanistic rationale and translational strategy for leveraging Molidustat (BAY85-3934), a novel HIF prolyl hydroxylase inhibitor, in the context of chronic kidney disease anemia. Integrating new research on the regulation of HIF-1α and the role of Septin4 in hypoxia-induced injury, we provide strategic guidance for researchers seeking to model erythropoietin stimulation and oxygen-sensing pathways. Key experimental, clinical, and workflow considerations are discussed, positioning Molidustat as a next-generation tool for both discovery and therapeutic development.

• Anti-RPS6 (7B10) Antibody: A Next-Gen Tool for Ribosome Biog

  2026-07-13

  Explore how the Anti-RPS6 antibody advances cell signaling and ribosome biogenesis research. This article uniquely connects RPS6 detection to new insights in cancer biology, providing depth beyond current literature.

• Honokiol: Advanced Workflows for NF-κB Pathway Inhibition

  2026-07-13

  Honokiol, a high-purity small molecule from APExBIO, provides unparalleled precision for dissecting NF-κB signaling, oxidative stress, and angiogenesis in cancer and inflammation research. This guide translates recent immunometabolic breakthroughs into actionable protocols and troubleshooting strategies—a must-read for researchers seeking rigor and reproducibility in complex cell-based assays.

• OLIG2 Modifications Drive Glioma Invasion via TGF-β Pathway

  2026-07-12

  Singh et al. reveal that post-translational modifications of OLIG2 control a critical switch between proliferation and invasion in glioma cells by modulating TGF-β2 signaling. This mechanistic insight into OLIG2-dependent invasion highlights new opportunities to target TGF-β pathway components for limiting glioblastoma dissemination.

• Letrozole’s Mechanistic Edge: Strategy for Translational Onc

  2026-07-10

  Explore how Letrozole, a potent non-steroidal aromatase inhibitor, is reshaping translational breast cancer research. This thought-leadership article moves beyond product basics to deliver mechanistic insight, protocol strategy, and competitive context, bridging laboratory rigor with the evolving demands of biomarker-driven, personalized oncology.

• 5-Ethynyl-2'-deoxyuridine: Precision Cell Proliferation Assa

  2026-07-09

  5-Ethynyl-2'-deoxyuridine (5-EdU) revolutionizes cell proliferation assays through rapid, antibody-free click chemistry detection of S phase DNA synthesis. Discover protocol optimizations, advanced troubleshooting, and translational insights from recent spermatogonial stem cell research to maximize sensitivity and reproducibility in applications from tumor growth to tissue regeneration.

• Fe3O4@ZIF-8 Nanoparticles: Dual Antibacterial and Osteogenic

  2026-07-09

  This study introduces multifunctional Fe3O4@ZIF-8 core–shell nanoparticles for simultaneous infection control and bone regeneration in jaw osteomyelitis. By leveraging pH-responsive Zn2+ release and superparamagnetic Fe3O4 cores, the approach addresses persistent infection and bone defects, holding promise for translational advances in antibacterial therapy.

• Wnt Agonist 1 (BML-284): Optimizing Wnt Pathway Activation i

  2026-07-08

  Wnt agonist 1 (BML-284) empowers researchers with precise, reproducible control over canonical Wnt signaling, enabling advanced modeling of developmental biology and chemoresistance. This guide translates cutting-edge evidence into actionable workflows, troubleshooting tips, and best practices for maximizing the impact of Wnt pathway cellular differentiation research.

• Elobixibat Hydrate: Strategic Frontiers in GI and Metabolic

  2026-07-08

  This thought-leadership article unpacks the mechanistic, translational, and strategic value of Elobixibat hydrate as a selective ileal bile acid transporter inhibitor. Integrating insights from foundational and recent studies, it offers actionable guidance for translational researchers seeking to leverage this compound in chronic idiopathic constipation, metabolic disease, and advanced experimental workflows. The piece highlights APExBIO’s product advantages, protocol recommendations, and the evolving landscape of IBAT inhibitors.

• OSMI-1: Precision OGT Inhibition for Decoding O-GlcNAcylatio

  2026-07-07

  Explore how OSMI-1, a potent O-GlcNAc transferase inhibitor, enables high-resolution investigation of protein O-GlcNAc modification in placental ferroptosis and trophoblast syncytialization. This article reveals advanced assay strategies, mechanistic insights, and practical considerations overlooked by existing content.

• 3-Bromopyruvate and Cetuximab Synergy in Overcoming CRC Resi

  2026-07-07

  This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab overcomes resistance in colorectal cancer models by inducing autophagy-dependent ferroptosis and apoptosis. The mechanistic findings highlight the FOXO3a/AMPKα/pBeclin1 and FOXO3a/PUMA pathways as critical targets for refractory metastatic colorectal cancer.

• Decoding mRNA Delivery: Mechanisms, Metrics, and Translation

  2026-07-06

  This thought-leadership article bridges mechanistic insight and strategic guidance for translational researchers in the mRNA therapeutics field. It explores how ARCA Cy5 EGFP mRNA (5-moUTP) from APExBIO enables rigorous, quantitative evaluation of mRNA delivery and translation, integrating recent advances in LNP formulation and immune evasion. The discussion positions this tool as pivotal in overcoming experimental bottlenecks and catalyzing preclinical innovation, and provides actionable protocol parameters for immediate adoption.

• Single-Dose Gepotidacin for Gonorrhea: Phase 2 Efficacy Evid

  2026-07-06

  This article reviews a phase 2 trial evaluating single-dose oral gepotidacin for uncomplicated urogenital gonorrhea, demonstrating ≥95% microbiological cure rates. The findings highlight gepotidacin’s potential as a novel oral therapy against Neisseria gonorrhoeae amid escalating antibiotic resistance.

• Quantitative Analysis of Leucomycin Impurities via HPLC-CAD/

  2026-07-05

  Wang et al. developed and validated high-performance liquid chromatography methods with charged aerosol detection (HPLC-CAD) and ultraviolet detection (HPLC-UV) for quantifying impurities in leucomycin (kitasamycin) bulk drugs and tablets. This innovation addresses the challenge of impurity quantitation in the absence of reference standards, improving the reliability of quality control for macrolide antibiotics.

460 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page